Provided are a sesquiterpene derivative represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition including the same and a PD-1 antibody as active components, as well as a preparation method and use thereof; in formula (I), R.sub.1 and R.sub.2 independently are selected from the group consisting of alkyl and hydroxyalkyl, with the proviso that R.sub.1 and R.sub.2 are not simultaneously methyl.

##STR00001##

Disclosed are a pharmaceutically acceptable salt of an MOR receptor agonist, and a polymorph thereof and the use thereof. Specifically, disclosed are a pharmaceutically acceptable salt of (4S,6S)-6-isopropyl-N-(2-((R)-9-(pyridin-2yl)-6-oxa spiro[4.5]decyl-9-yl)ethyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-amine, and a polymorph thereof and the use thereof. In addition, further disclosed are a pharmaceutical composition containing the pharmaceutically acceptable salt of the compound or the polymorph thereof, and the use thereof.

Disclosed are a pharmaceutically acceptable salt of an MOR receptor agonist, and a polymorph thereof and the use thereof. Specifically, disclosed are a pharmaceutically acceptable salt of (4S,6S)-6-isopropyl-N-(2-((R)-9-(pyridin-2yl)-6-oxa spiro[4.5]decyl-9-yl)ethyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-amine, and a polymorph thereof and the use thereof. In addition, further disclosed are a pharmaceutical composition containing the pharmaceutically acceptable salt of the compound or the polymorph thereof, and the use thereof.

The present invention relates to a zirconium-based metal organic framework comprising at least a tetravalent zirconium ion (Zr.sup.4+) and a bidentate or tridentate linking ligand bonding the said tetravalent zirconium ion (Zr.sup.4+). Moreover, the present invention also relates to a method for preparing the zirconium-based metal organic framework comprising the steps of: (a) preparing a reaction mixture comprising a zirconium compound, a linking ligand and, optionally, a modulating agent in a solvent; (b) heating the reaction mixture obtained from step (a); and (c) washing a reaction product obtained from step (b) with the solvent and drying the reaction product. The zirconium-based metal organic framework according to the present invention is suitable for using in a process for removing heavy metals in the condensate, especially using in the adsorption, removal, or reduction of arsenic and mercury contents in the condensate.

The present invention relates to a zirconium-based metal organic framework comprising at least a tetravalent zirconium ion (Zr.sup.4+) and a bidentate or tridentate linking ligand bonding the said tetravalent zirconium ion (Zr.sup.4+). Moreover, the present invention also relates to a method for preparing the zirconium-based metal organic framework comprising the steps of: (a) preparing a reaction mixture comprising a zirconium compound, a linking ligand and, optionally, a modulating agent in a solvent; (b) heating the reaction mixture obtained from step (a); and (c) washing a reaction product obtained from step (b) with the solvent and drying the reaction product. The zirconium-based metal organic framework according to the present invention is suitable for using in a process for removing heavy metals in the condensate, especially using in the adsorption, removal, or reduction of arsenic and mercury contents in the condensate.

This salt of the compound represented by formula (I) and crystals thereof are applicable as an active pharmaceutical ingredient of pharmaceutical products.

##STR00001##

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The maleate novel crystalline forms of compound of Formula (I) in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.

##STR00001##

The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The maleate novel crystalline forms of compound of Formula (I) in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.

##STR00001##